Relafen and Knee joint replacement - a phase IV clinical study of FDA data

Summary:

Knee joint replacement is reported as a side effect among people who take Relafen (nabumetone), especially for people who are female, 60+ old, also take Methotrexate, and have Rheumatoid arthritis.

The phase IV clinical study analyzes which people have Knee joint replacement when taking Relafen. It is created by eHealthMe based on reports of 5,961 people who have side effects when taking Relafen from the FDA, and is updated regularly.

What is Relafen?

Relafen has active ingredients of nabumetone. It is often used in arthritis. eHealthMe is studying from 6,243 Relafen users. Check the latest studies of Relafen.

What is Knee joint replacement?

Knee joint replacement is found to be associated with 945 drugs and 1,232 conditions by eHealthMe. Check the latest studies of Knee joint replacement.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 03, 2026

5,961 people reported to have side effects when taking Relafen.
Among them, 20 people (0.34%) have Knee joint replacement.

Could Relafen cause Knee joint replacement?

Among these 20 people:

What is the gender of people who have Knee joint replacement when taking Relafen? *

female: 70 %
male: 30 %

What is the age of people who have Knee joint replacement when taking Relafen? *

What are other drugs people take besides Relafen? *

What are other side effects people have besides Knee joint replacement? *

Heart Attack: 4 people, 20.00%
Chest Pain: 4 people, 20.00%
Coronary Heart Disease (narrowing or blockage of the coronary arteries): 3 people, 15.00%
Injection Site Haemorrhage (bleeding from injection site): 3 people, 15.00%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 3 people, 15.00%
Oedema Peripheral (superficial swelling): 3 people, 15.00%
Arthropathy: 3 people, 15.00%
Arthritis Infective (purulent invasion of a joint by an infectious agent which produces arthritis): 2 people, 10.00%
The Flu (the flu is caused by an influenza virus): 2 people, 10.00%
Intervertebral Disc Disorder (spinal disc disorder): 2 people, 10.00%

What are the existing conditions these people have? *

High Blood Pressure: 6 people, 30.00%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 6 people, 30.00%
Joint Pain: 3 people, 15.00%
High Blood Cholesterol: 3 people, 15.00%
Blood Growth Hormone Decreased: 2 people, 10.00%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 2 people, 10.00%
Breast Cancer: 2 people, 10.00%
Growth Hormone Deficiency: 2 people, 10.00%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 2 people, 10.00%
Bone Disorder: 1 person, 5.00%

* Approximation only. Some reports may have incomplete information.

Do you take Relafen and have Knee joint replacement?

- Check whether Knee joint replacement is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Relafen:

Relafen (6,243 reports)

Browse all side effects of Relafen:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Knee joint replacement:

Knee joint replacement (945 drugs)

Browse all the conditions that are associated with Knee joint replacement:

Knee joint replacement (1,232 conditions)

Related publications that referenced our studies

Hung SC, Liao KF, Hung HC, Lin CL, Lai SW, Lin CH, "Nabumetone use and risk of acute pancreatitis in a case-control study", Pancreatology, 2016 Jun .
Hung SC, Liao KF, Hung HC, Lin CL, Lai SW, Lin CH, "Nabumetone use and risk of acute pancreatitis in a case-control study", Pancreatology, 2016 Jun .

How the study uses the data?

The study uses data from the FDA. It is based on nabumetone (the active ingredients of Relafen) and Relafen (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.